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Background:Recently, a number of antibodies capable of broadly
neutralizing HIV have been isolated from HIV infected patients,
stimulating efforts to elicit their production in naive individuals.
As an alternative to vaccination, we recently described vectored
immunoprophylaxis (VIP) as an approach capable of generating
high serum concentrations of a desired monoclonal antibody in
mice following a single intramuscular injection of a specialized
adeno associated viral vector (AAV). Mice that received VIP en-
coding b12, VRC01 or VRC07 antibodies demonstrated long-term
circulating antibody expression in serum, and VIP-treated hu-
manized mice exhibited remarkable protection against high dose,
intravenous challenge with CXCR4-tropic HIV. However, most
human infections are initiated by transmission of CCR5-tropic
strains through mucosal tissues.
Methods: To measure the efﬁcacy of VIP against clinically rele-
vant strains, we humanized VIP-treated mice by adoptive trans-
fer of peripheral bloodmononuclear cells (PBMC) and challenged
these animals with CCR5-tropic HIV strains including JR-CSF, as
well as REJO.c, a transmitted molecular founder. To determine
the ability of VIP to prevent mucosal transmission of clinically
relevant HIV, we developed a repetitive intravaginal challenge
model in VIP-treated BLT humanized mice that were challenged
weekly with JR-CSF or REJO.c and monitored for infection.
Results: PBMC humanized mice expressing b12 or VRC01 were
protected from intravenous challenge with JR-CSF. In contrast,
the b12-resistant REJO.c strain readily infected PBMC humanized
mice expressing b12 antibody, while mice expressing VRC01 dem-
onstrated nearly complete protection following challenge. Intra-
vaginally challenged BLT animals expressing luciferase as a control
all became infected over the study period while a majority of ani-
mals expressing VRC01 or VRC07 had no detectable HIV infection
despite repeated intravaginal challenges with JR-CSF or REJO.c.
Conclusion: VIP is capable of protecting humanized mice from
challenge by diverse HIV strains and can prevent vaginal trans-
mission. These ﬁndings warrant continued development of VIP
as a novel approach for HIV prevention.
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Background: Integrase defective lentiviral vector (IDLV) ex-
pressing antigens induces long-lasting and protective immune
responses in mice after a single immunization. IDLV persists at
the site of inoculum in the absence of integration, resulting in a
prolonged antigen expression. The aim of this study was to
demonstrate in monkeys that immunization with IDLV deliver-
ing the prototype clade C transmitted founder HIV-1 Env
1086.Cgp140 (IDLV-Env) induces sustained and functional anti-
Env antibodies (Abs) and T cell responses.
Methods: Six rhesus monkeys were primed with IDLV-Env and
boosted at 1 year after priming. An analysis of Ab response was
assessed over time. Binding, epitope mapping, neutralizing ac-
tivity and ADCC of anti-Env Abs were evaluated at sequential
time points. IFNg ELISPOT was performed to evaluate persis-
tence and presence of functional Env-speciﬁc T cells.
Results: A single immunization with IDLV-Env induced strong
and prolonged immune responses. Anti-Env Abs peaked between
2 and 6 weeks and were still present at 1 year after the vaccination.
All monkeys showed neutralizing Abs in serum samples starting
from 6 weeks and peaking at 14 weeks after immunization. Three
out of 6 monkeys showed ADCC in serum samples and 4 out of 6
had detectable anti-V1V2 Abs. High levels of IFNg producing
T cells were elicited in all monkeys, decreasing over time, but still
detectable up to 1 year after immunization. Abs and T cell re-
sponses showed a signiﬁcant increase after the boost.
Conclusion: This is the ﬁrst demonstration that an IDLV-based
vaccine expressing HIV Envelope is able to induce functional,
comprehensive and persistent immune responses in non-human
primates. These results support the further evaluation of IDLV as
a delivery system in the context of a HIV-1 vaccine.
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Background: PG9 and PG16 are founding members of a class
of broadly neutralizing antibodies (BNAbs) that target V2-
dependent quaternary neutralization epitopes (QNEs) that in-
cludes the conserved N-linked glycan at position N160. CAP256
sera contain related highly potent BNAbs that target an over-
lapping epitope not dependent on N160. Commonly used SHIVs
(SHIV-SF162P3, SHIV-1157ipd3N4, SHIV-AD8, and SHIV-BaL)
poorly express these epitopes. Two changes in SHIV-1157ipd3N4
Env, Q170K and I192R, conferred sensitivity to QNE-speciﬁc
NAbs. Thismutant is infectious andpathogenic in pigtailmacaques.
Methods: Tracking the course of infection with SHIV1157 +QNE
should allow the recapitulation of steps leading to the production
of QNE-speciﬁc BNAbs. We monitored the development of an-
tibody responses and evolution of Env sequences in infected
macaques. SGA was used to amplify sequences; representative
sequences were cloned for analysis of neutralization sensitivity.
Results: Autologous neutralizing antibodies were detected at
week 16 post-infection (PI). At week 16 PI, 12/13 sequences con-
tained mutations at position K143 that conferred resistance to sera
fromweeks 16 - 32 PI. These viruseswere sensitive toweek 35 sera,
indicating the development of a new antibody response. At week
24, only*half of the sequences had K143 mutations, and the re-
maining had V1 deletions and mutations elsewhere in Env, in-
cluding the K169E mutation that in other Env contexts conferred
resistance to neutralization by PG9, PG16, and CAP256 sera.
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